Unexpected adverse reaction: An adverse reaction, the nature, severity or outcome of which is not consistent with the summary of product characteristics.
In overdoses up to 15 g, no unexpected adverse reactions were reported.
In phase 1 clinical trials, healthy subjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpected adverse reactions.
In phase 1 clinical trials, healthy subjects who received up to 100 mg once daily for up to 14 days or single doses up to 200 mg had no unexpected adverse reactions.
No unexpected adverse events were reported (see section 4.2).
No unexpected adverse events were reported (see section 4.2).
Unexpected adverse events (not mentioned on the product package leaflet)
Overdose: In overdoses up to 15 g, no unexpected adverse effects were reported.
However, discovered an unexpected side effect there is a risk of uterine sarcoma.
However, it found an unexpected side effect – there is the risk of uterine
Pharmacovigilance therefore aims to detect any emerging signs as quickly as possible, both unexpected adverse effects and known adverse effects with an unexpected frequency or severity.
The role of pharmacovigilance is to detect any emerging signal as quickly as possible, whether it involves an unknown adverse event or a known effect that has unexpected frequency or severity.
The role of pharmacovigilance is to detect any emerging signal as quickly as possible, whether it involves an unknown adverse event or a known effect that has unexpected frequency or severity.
No unexpected adverse events have been reported in cancer patients receiving Sandostatin at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.
No unexpected adverse events have been reported in cancer patients receiving octreotide at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.
Drug Induced Pneumonitis Secondary to Treatment with Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir (VIEKIRA PAK®) for Chronic Hepatitis C: Case Report of an Unexpected Life-Threatening Adverse Reaction
No unexpected adverse events have been reported in cancer patients receiving octreotide at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.
No unexpected adverse events have been reported in cancer patients receiving octreotide at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.
No unexpected adverse events have been reported in cancer patients receiving Sandostatin at doses of 3,000-30,000 micrograms/day in divided doses subcutaneously.
Requêtes fréquentes français :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Requêtes fréquentes anglais :1-200, -1k, -2k, -3k, -4k, -5k, -7k, -10k, -20k, -40k, -100k, -200k, -500k, -1000k,
Traduction Translation Traducción Übersetzung Tradução Traduzione Traducere Vertaling Tłumaczenie Mετάφραση Oversættelse Översättning Käännös Aistriúchán Traduzzjoni Prevajanje Vertimas Tõlge Preklad Fordítás Tulkojumi Превод Překlad Prijevod 翻訳 번역 翻译 Перевод